No Result
View All Result
Success American Investors
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
No Result
View All Result
Success American Investors
No Result
View All Result
Home Stock

HairLabs Launches Anti Grey 1.0 – World’s First AI-Powered Hair Supplement Designed to Protect Stem Cells

by
June 18, 2025
in Stock
0
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

London-based biotech firm HairLabs, known for its cutting-edge work in hair healthspan, has today unveiled Anti Grey 1.0 – a pioneering daily nutraceutical created to support the preservation of melanocyte stem cells (MSCs), the key to maintaining natural hair pigmentation. The product officially goes on sale from Friday 13 June 2025 at hairlabs.ai, with both one-off purchases and subscription…

Source

Previous Post

CMD Recruitment Warns Employers Risk Lagging Behind on Staff Benefits

Next Post

UK watchdog fines 23andMe for ‘profoundly damaging’ data breach

Next Post
UK watchdog fines 23andMe for ‘profoundly damaging’ data breach

UK watchdog fines 23andMe for ‘profoundly damaging’ data breach

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!
  • Trending
  • Comments
  • Latest
Vertica: The new Israeli start-up challenger to Viagra proving ‘life-changing’ for men with ED

Vertica: The new Israeli start-up challenger to Viagra proving ‘life-changing’ for men with ED

February 14, 2024
Brighton Palace Pier put up for sale as rising costs bite leisure sector

Brighton Palace Pier put up for sale as rising costs bite leisure sector

January 3, 2026

New working paper: “Shifting Perspectives: An Updated Survey of Environmental and Natural Resource Economists”

May 5, 2025

Last Day to Give in 2023!

December 31, 2023
The System That Rewards Excess—the Incentives Behind Overdiagnosis, Overtreatment, and Polypharmacy

The System That Rewards Excess—the Incentives Behind Overdiagnosis, Overtreatment, and Polypharmacy

0

0

0

0
The System That Rewards Excess—the Incentives Behind Overdiagnosis, Overtreatment, and Polypharmacy

The System That Rewards Excess—the Incentives Behind Overdiagnosis, Overtreatment, and Polypharmacy

January 12, 2026
When Politics Replaces Policy: The Case for Reviving Limited Government

When Politics Replaces Policy: The Case for Reviving Limited Government

January 12, 2026
Bombing Iran Risks Repeating Past Mistakes

Bombing Iran Risks Repeating Past Mistakes

January 12, 2026
National Pharmacist Day: The Most Underused Clinicians in Health Care

National Pharmacist Day: The Most Underused Clinicians in Health Care

January 12, 2026

Recent News

The System That Rewards Excess—the Incentives Behind Overdiagnosis, Overtreatment, and Polypharmacy

The System That Rewards Excess—the Incentives Behind Overdiagnosis, Overtreatment, and Polypharmacy

January 12, 2026
When Politics Replaces Policy: The Case for Reviving Limited Government

When Politics Replaces Policy: The Case for Reviving Limited Government

January 12, 2026
Bombing Iran Risks Repeating Past Mistakes

Bombing Iran Risks Repeating Past Mistakes

January 12, 2026
National Pharmacist Day: The Most Underused Clinicians in Health Care

National Pharmacist Day: The Most Underused Clinicians in Health Care

January 12, 2026

Disclaimer: SuccessAmericanInvestors.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2026 SuccessAmericanInvestors. All Rights Reserved.

No Result
View All Result
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock

Copyright © 2026 SuccessAmericanInvestors. All Rights Reserved.